APOA1

protein-coding

apolipoprotein A1, the group of Apolipoproteins

Gene summary

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The encoded preproprotein is proteolytically processed to generate the mature protein, which promotes cholesterol efflux from tissues to the liver for excretion, and is a cofactor for lecithin cholesterolacyltransferase (LCAT), an enzyme responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein. [provided by RefSeq, Dec 2015]

MANE transcript

NM_000039.3

Inheritance

SD, AD, AR

ClinVar variants

P:34U:197B:120

Top phenotype

Amyloidosis, hereditary systemic 3; Hypoalphalipoproteinemia, primary 2

gnomAD constraint

pLI —, LoF o/e 0.68

Max pathogenic AF

—

Genomic locus

chr11:116,835,751-116,837,622

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~1.9 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

hypoalphalipoproteinemia, primary, 2STRONG

Inheritance Pattern: SD

Disease ID:MONDO:0032766

Submitter: PanelApp Australia

apolipoprotein A-I deficiencySUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0100189

Submitter: Orphanet

amyloidosis, hereditary systemic 3STRONG

Inheritance Pattern: AD

Disease ID:MONDO:0971008

Submitter: PanelApp Australia

familial visceral amyloidosisSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007099

Submitter: Labcorp Genetics (formerly Invitae)

familial visceral amyloidosisSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007099

Submitter: Ambry Genetics

hypoalphalipoproteinemia, primary, 2STRONG

Inheritance Pattern: AR

Disease ID:MONDO:0032766

Submitter: Labcorp Genetics (formerly Invitae)

AApoAI amyloidosisSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019731

Submitter: Orphanet

Clinical Genomic Database (CGD)

Amyloidosis, hereditary systemic 3; Hypoalphalipoproteinemia, primary 2AD/AR

Manifestation: Cardiovascular; Endocrine; Dermatologic; Gastrointestinal; Ophthalmologic; Renal

Intervention: Cardiovascular; Endocrine; Gastrointestinal; Pharmacogenomic

Rationale: In Hypoalphalipoproteinemia, primary 2, intervention to decrease risk factors contributing to cardiovascular disease (eg, CAD and stroke), as well as early surveillance and intervention in the case of findings such as CAD, may be beneficial; In Hereditary amyloidosis, individuals may manifest with sequelae affecting multiple organ systems, and awareness may allow early diagnossi and medical management (eg, related to endocrine or renal insufficiency); Liver transplantation can correct the underlying metabolic defect

Comments: Though manifestations have been described in adults, surveillance and interventions should likely begin in the pediatric period; Hypoalphalipoproteinemia, primary, 2, intermediate has not been described as involving cardiovascular risk

Refs: 4304452; 7430351; 6776144; 7249374; 7080131; 7078608; 6818131; 6308458; 6131168; 6401735; 6401735; 3118360; 3141894; 2512329; 2512329; 1901417; 1502149; 8240372; 8282791; 7981179; 8675681; 9514407; 9916936; 10487826; 9931341; 12270762; 12050338; 16023124; 17991432; 21122686; 21443680; 21875686; 29446975; 30665372Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to APOA1 variants in ClinVar

22 Conditions Cataloged
not providedTotal: 251
Cardiovascular phenotypeTotal: 191
Hypoalphalipoproteinemia, primary, 2Total: 66
Hypoalphalipoproteinemia, primary, 2, intermediateTotal: 59
not specifiedTotal: 55
Familial amyloid polyneuropathy, Iowa typeTotal: 50
Familial visceral amyloidosis, Ostertag typeTotal: 32
APOA1-related disorderTotal: 16

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_000039.3. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
3
clinvar
99
clinvar
102
missense
14
clinvar
2
clinvar
185
clinvar
19
clinvar
2
clinvar
222
nonsense
8
clinvar
2
clinvar
5
clinvar
15
start loss
0
frameshift
1
clinvar
4
clinvar
3
clinvar
8
splice donor/acceptor (+/-2bp)
3
clinvar
1
clinvar
4
Total2681971182351

Highest pathogenic variant AF is 0.000012394845

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 68 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_000039.3RefSeqNP_000030.13MANE Select
ENST00000236850.5EnsemblENSP00000236850.33MANE Select
NM_001318017.2RefSeqNP_001304946.13Standard
NM_001318018.2RefSeqNP_001304947.13Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Fat digestion and absorption - Homo sapiens (human)
  • Vitamin digestion and absorption - Homo sapiens (human)
  • African trypanosomiasis - Homo sapiens (human)
  • Cholesterol metabolism - Homo sapiens (human)
  • PPAR signaling pathway - Homo sapiens (human)

Biological Process

  • retinoid metabolic process
  • regulation of protein phosphorylation
  • endothelial cell proliferation
  • platelet degranulation
  • negative regulation of cytokine secretion involved in immune response

Molecular Function

  • amyloid-beta binding
  • protein binding
  • phospholipid binding
  • phospholipid transporter activity
  • high-density lipoprotein particle binding

Cellular Component

  • extracellular region
  • extracellular space
  • nucleus
  • early endosome
  • endoplasmic reticulum lumen

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000236850
Coding exons
3
Length
2200
Individuals with no LoFs
125741
Homozygous LoFs
0
Heterozygous LoFs
7
Defined
125748
p
0.0000278
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense0.5101351530.8840.000007791740
Missense (PolyPhen)3543.3410.80754556
Synonymous-0.8398071.01.130.00000386523
Loss of Function0.87968.820.6803.84e-796

Population LoF Frequency

PopulationCAFp-valueStatus
African00.0absent
Latino/Admixed American0.0000580.000058rare
Ashkenazi Jewish00.0absent
East Asian0.0000540.000054rare
Finnish00.0absent
European (Non-Finnish)0.0000270.000026rare
South Asian0.0000330.000033rare
Other00.0absent

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. {ECO:0000269|PubMed:1909888}.;
Disease
DISEASE: High density lipoprotein deficiency 2 (HDLD2) [MIM:604091]: Inherited as autosomal dominant trait. It is characterized by moderately low HDL cholesterol, predilection toward premature coronary artery disease (CAD) and a reduction in cellular cholesterol efflux. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: High density lipoprotein deficiency 1 (HDLD1) [MIM:205400]: Recessive disorder characterized by absence of high density lipoprotein (HDL) cholesterol from plasma, accumulation of cholesteryl esters, premature coronary artery disease (CAD), hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Note=APOA1 mutations may be involved in the pathogenesis of amyloid polyneuropathy-nephropathy Iowa type, also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III (PubMed:3142462 and PubMed:2123470). The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis.; DISEASE: Amyloidosis 8 (AMYL8) [MIM:105200]: A form of hereditary generalized amyloidosis. Clinical features include extensive visceral amyloid deposits, renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. There is no involvement of the nervous system. {ECO:0000269|PubMed:1502149, ECO:0000269|PubMed:2123470, ECO:0000269|PubMed:3142462, ECO:0000269|PubMed:8208902}. Note=The disease is caused by mutations affecting the gene represented in this entry.;

Intolerance Scores

LoFtool
0.397
RVIS EVS
-0.47
RVIS percentile EVS
23.04

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.998

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.